These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25793625)

  • 81. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006).
    Ishii Y; Tateda K; Yamaguchi K;
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):177-83. PubMed ID: 17931820
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
    Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
    Llanes C; Pourcel C; Richardot C; Plésiat P; Fichant G; Cavallo JD; Mérens A;
    J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
    Sader HS; Mendes RE; Duncan LR; Carvalhaes CG; Castanheria M
    J Antimicrob Chemother; 2022 Sep; 77(10):2642-2649. PubMed ID: 35897129
    [TBL] [Abstract][Full Text] [Related]  

  • 86. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
    Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
    J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 88. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms.
    Jamieson CE; Lambert PA; Simpson IN
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2615-8. PubMed ID: 12878527
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.
    Carsenti-Etesse H; Cavallo JD; Roger PM; Ziha-Zarifi I; Plesiat P; Garrabé E; Dellamonica P
    Clin Microbiol Infect; 2001 Mar; 7(3):144-51. PubMed ID: 11318813
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Deciphering β-lactamase-independent β-lactam resistance evolution trajectories in Pseudomonas aeruginosa.
    Cabot G; Florit-Mendoza L; Sánchez-Diener I; Zamorano L; Oliver A
    J Antimicrob Chemother; 2018 Dec; 73(12):3322-3331. PubMed ID: 30189050
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Polyamine effects on antibiotic susceptibility in bacteria.
    Kwon DH; Lu CD
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2070-7. PubMed ID: 17438056
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
    Rodríguez-Martínez JM; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2009 May; 53(5):1766-71. PubMed ID: 19258272
    [TBL] [Abstract][Full Text] [Related]  

  • 94. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.
    Carsenti-Etesse H; Cavallo JD; Roger PM; Ziha-Zarifi I; Plesiat P; Garrabe E; Dellamonica P
    Chirurgia (Bucur); 2002; 97(2):151-9. PubMed ID: 12731225
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mutant prevention concentrations of four carbapenems against gram-negative rods.
    Credito K; Kosowska-Shick K; Appelbaum PC
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2692-5. PubMed ID: 20308376
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
    Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
    Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
    Keepers TR; Gomez M; Celeri C; Nichols WW; Krause KM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5297-305. PubMed ID: 24957838
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Penicillin-binding protein 3 sequence variations reduce susceptibility of Pseudomonas aeruginosa to β-lactams but inhibit cell division.
    Glen KA; Lamont IL
    J Antimicrob Chemother; 2024 Sep; 79(9):2170-2178. PubMed ID: 39001778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.